176 related articles for article (PubMed ID: 15161071)
1. Protection against plague afforded by immunisation with DNA vaccines optimised for expression of the Yersinia pestis V antigen.
Garmory HS; Freeman D; Brown KA; Titball RW
Vaccine; 2004 Feb; 22(8):947-57. PubMed ID: 15161071
[TBL] [Abstract][Full Text] [Related]
2. Expression of an F1/V fusion protein in attenuated Salmonella typhimurium and protection of mice against plague.
Leary SE; Griffin KF; Garmory HS; Williamson ED; Titball RW
Microb Pathog; 1997 Sep; 23(3):167-79. PubMed ID: 9281474
[TBL] [Abstract][Full Text] [Related]
3. Concomitant administration of Yersinia pestis specific monoclonal antibodies with plague vaccine has a detrimental effect on vaccine mediated immunity.
Eyles JE; Butcher WA; Titball RW; Hill J
Vaccine; 2007 Oct; 25(42):7301-6. PubMed ID: 17869388
[TBL] [Abstract][Full Text] [Related]
4. Small protective fragments of the Yersinia pestis V antigen.
Vernazza C; Lingard B; Flick-Smith HC; Baillie LW; Hill J; Atkins HS
Vaccine; 2009 May; 27(21):2775-80. PubMed ID: 19366573
[TBL] [Abstract][Full Text] [Related]
5. Protection against aerosolized Yersinia pestis challenge following homologous and heterologous prime-boost with recombinant plague antigens.
Glynn A; Roy CJ; Powell BS; Adamovicz JJ; Freytag LC; Clements JD
Infect Immun; 2005 Aug; 73(8):5256-61. PubMed ID: 16041052
[TBL] [Abstract][Full Text] [Related]
6. Yersinia outer proteins (YOPS) E, K and N are antigenic but non-protective compared to V antigen, in a murine model of bubonic plague.
Leary SE; Griffin KF; Galyov EE; Hewer J; Williamson ED; Holmström A; Forsberg A; Titball RW
Microb Pathog; 1999 Mar; 26(3):159-69. PubMed ID: 10089156
[TBL] [Abstract][Full Text] [Related]
7. Neutralization of Yersinia pestis-mediated macrophage cytotoxicity by anti-LcrV antibodies and its correlation with protective immunity in a mouse model of bubonic plague.
Zauberman A; Cohen S; Levy Y; Halperin G; Lazar S; Velan B; Shafferman A; Flashner Y; Mamroud E
Vaccine; 2008 Mar; 26(13):1616-25. PubMed ID: 18304706
[TBL] [Abstract][Full Text] [Related]
8. Kinetics of the immune response to the (F1+V) vaccine in models of bubonic and pneumonic plague.
Williamson ED; Stagg AJ; Eley SM; Taylor R; Green M; Jones SM; Titball RW
Vaccine; 2007 Jan; 25(6):1142-8. PubMed ID: 17101198
[TBL] [Abstract][Full Text] [Related]
9. Expression of Yersinia pestis V antigen in attenuated salmonella typhimurium: development of a novel vaccine for plague.
Leary SE; Eley SM; Williamson ED; Titball RW
Contrib Microbiol Immunol; 1995; 13():216-7. PubMed ID: 8833838
[No Abstract] [Full Text] [Related]
10. Involvement of CD8+ T cell-mediated immune responses in LcrV DNA vaccine induced protection against lethal Yersinia pestis challenge.
Wang S; Goguen JD; Li F; Lu S
Vaccine; 2011 Sep; 29(39):6802-9. PubMed ID: 21199697
[TBL] [Abstract][Full Text] [Related]
11. Cell-mediated immune response and Th/Th cytokine profile of B-T constructs of F1 and V antigen of Yersinia pestis.
Gupta G; Khan AA; Rao DN
Scand J Immunol; 2010 Mar; 71(3):186-98. PubMed ID: 20415784
[TBL] [Abstract][Full Text] [Related]
12. Immunogenicity and efficacy of an anthrax/plague DNA fusion vaccine in a mouse model.
Albrecht MT; Eyles JE; Baillie LW; Keane-Myers AM
FEMS Immunol Med Microbiol; 2012 Aug; 65(3):505-9. PubMed ID: 22515653
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity of the rF1+rV vaccine for plague with identification of potential immune correlates.
Williamson ED; Flick-Smith HC; Waters E; Miller J; Hodgson I; Le Butt CS; Hill J
Microb Pathog; 2007 Jan; 42(1):11-21. PubMed ID: 17107769
[TBL] [Abstract][Full Text] [Related]
14. A Salmonella enterica serovar Typhi vaccine expressing Yersinia pestis F1 antigen on its surface provides protection against plague in mice.
Morton M; Garmory HS; Perkins SD; O'Dowd AM; Griffin KF; Turner AK; Bennett AM; Titball RW
Vaccine; 2004 Jun; 22(20):2524-32. PubMed ID: 15193377
[TBL] [Abstract][Full Text] [Related]
15. CpG oligodeoxynucleotides augment the murine immune response to the Yersinia pestis F1-V vaccine in bubonic and pneumonic models of plague.
Amemiya K; Meyers JL; Rogers TE; Fast RL; Bassett AD; Worsham PL; Powell BS; Norris SL; Krieg AM; Adamovicz JJ
Vaccine; 2009 Apr; 27(16):2220-9. PubMed ID: 19428836
[TBL] [Abstract][Full Text] [Related]
16. N255 is a key residue for recognition by a monoclonal antibody which protects against Yersinia pestis infection.
Hill J; Leary S; Smither S; Best A; Pettersson J; Forsberg A; Lingard B; Lipka A; Brown KA; Williamson ED; Titball RW
Vaccine; 2009 Nov; 27(50):7073-9. PubMed ID: 19786138
[TBL] [Abstract][Full Text] [Related]
17. Stat 4 but not Stat 6 mediated immune mechanisms are essential in protection against plague.
Elvin SJ; Williamson ED
Microb Pathog; 2004 Oct; 37(4):177-84. PubMed ID: 15458778
[TBL] [Abstract][Full Text] [Related]
18. An optimized vaccine vector based on recombinant vesicular stomatitis virus gives high-level, long-term protection against Yersinia pestis challenge.
Palin A; Chattopadhyay A; Park S; Delmas G; Suresh R; Senina S; Perlin DS; Rose JK
Vaccine; 2007 Jan; 25(4):741-50. PubMed ID: 16959385
[TBL] [Abstract][Full Text] [Related]
19. Immunisation against plague by transcutaneous and intradermal application of subunit antigens.
Eyles JE; Elvin SJ; Westwood A; Lebutt CS; Alpar HO; Somavarapu S; Williamson ED
Vaccine; 2004 Oct; 22(31-32):4365-73. PubMed ID: 15474730
[TBL] [Abstract][Full Text] [Related]
20. Design and testing for a nontagged F1-V fusion protein as vaccine antigen against bubonic and pneumonic plague.
Powell BS; Andrews GP; Enama JT; Jendrek S; Bolt C; Worsham P; Pullen JK; Ribot W; Hines H; Smith L; Heath DG; Adamovicz JJ
Biotechnol Prog; 2005; 21(5):1490-510. PubMed ID: 16209555
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
